<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01787630</url>
  </required_header>
  <id_info>
    <org_study_id>NoHarm1</org_study_id>
    <nct_id>NCT01787630</nct_id>
  </id_info>
  <brief_title>To Evaluate the Technique and Effects of Separating the Prostate and Rectum With Hyaluronic Acid During Radiotherapy</brief_title>
  <acronym>NoHarm</acronym>
  <official_title>Initiating Phase II-III Study to Evaluate the Technique and Effects of Separating the Prostate From the Rectum With Hyaluronic Acid During Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anders Widmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Ume책</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ume책 University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The dominating problem after local radiotherapy of prostate cancer is rectal toxicity. If the
      rectum could be completely moved out of the treated volume, a substantial decrease of rectal
      toxicity seems reasonable. In this study we will develop and evaluate a new transrectal
      injection technique where hyaluronic acid (HA) is injected in the space between the prostate
      and the rectum prior to external beam radiotherapy to increase the physical distance between
      prostate and rectum.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remaining volume of HA</measure>
    <time_frame>24 month after end of radiotherapy</time_frame>
    <description>Measurement on the remaining volume of HA by MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>24 month after end of radiotherapy</time_frame>
    <description>Patient evaluation with questionnaires regarding Quality of Life and side effects after radiotherapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Prostatic Cancer</condition>
  <arm_group>
    <arm_group_label>Hyaluronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyaluronic acid will be injected in the space between the prostate and rectum prior to radiotherapy to perform a dorsal movement of rectum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyaluronic acid</intervention_name>
    <description>Injection in connection with ultrasound</description>
    <arm_group_label>Hyaluronic acid</arm_group_label>
    <other_name>NASHA Spacer Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically verified prostatic cancer

          -  Low or intermediate risk prostatic cancer

          -  Lymph node negative

          -  Suitable for radiotherapy

        Exclusion Criteria:

          -  Earlier treatment for prostatic cancer

          -  Unable to co-operate or suffering from any other form of disease that would interfere
             with the planned treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Widmark, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umea university, dept of oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of oncology, Kalmar Hospital</name>
      <address>
        <city>Kalmar</city>
        <zip>SE-39244</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of oncilogy, Sundsvall Hospital</name>
      <address>
        <city>Sundsvall</city>
        <zip>SE-851 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of oncology, University Hospital</name>
      <address>
        <city>Ume책</city>
        <zip>SE-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2013</study_first_submitted>
  <study_first_submitted_qc>February 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2013</study_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ume책 University</investigator_affiliation>
    <investigator_full_name>Anders Widmark</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <keyword>Prostatic cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Hyaluronic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

